141 related articles for article (PubMed ID: 35875118)
1. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201).
Song Y; Zhou K; Jin C; Qian Z; Hou M; Fan L; Li F; Ding K; Zhou H; Li X; Chen B; Sun X; Song X; Jiang M; Zhang Q; Liu L; Yu G; Hu Y; Zhao Z; Liu L; Xue H; Luo J; He B; Jin X; Zhao M; Li B; Xia Y; Zhu J
Front Oncol; 2022; 12():925236. PubMed ID: 35875118
[TBL] [Abstract][Full Text] [Related]
2. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
Huang Z; Pang X; Zhong T; Qu T; Chen N; Ma S; He X; Xia D; Wang M; Xia M; Li B
Front Immunol; 2022; 13():924542. PubMed ID: 35833116
[TBL] [Abstract][Full Text] [Related]
3. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).
Han C; Ye S; Hu C; Shen L; Qin Q; Bai Y; Yang S; Bai C; Zang A; Jiao S; Bai L
Front Oncol; 2021; 11():684867. PubMed ID: 34327136
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study.
Lin N; Zhang M; Bai H; Liu H; Cui J; Ke X; Zhang H; Liu L; Yan D; Jiang Y; Zang A; Qi J; Wang L; Liu Z; Xu B; Zhang Y; Zhang Z; Zhao X; Hu C; Yang S; Zhou H; Shi J; Shao Z; Xiang Y; Zhu J; Song Y; Zhu J
Eur J Cancer; 2022 Mar; 164():117-126. PubMed ID: 34462189
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204).
Zheng Y; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Xu N
Cancer; 2024 Feb; ():. PubMed ID: 38412283
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Yang L; Elstrom R; Huang J; Novotny W; Wei V; Zhu J
Leukemia; 2020 Feb; 34(2):533-542. PubMed ID: 31520078
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1.
Tao Y; Han J; Li Y
Invest New Drugs; 2022 Aug; 40(4):854-857. PubMed ID: 35503192
[TBL] [Abstract][Full Text] [Related]
8. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.
Song Y; Wu J; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
Clin Cancer Res; 2019 Dec; 25(24):7363-7369. PubMed ID: 31420358
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Shi Y; Cui J; Zhou H; Zhang X; Zou L; Cao J; Gao Y; Jin C; Li X; Liu H; Peng Z; Xie L; Zhang H; Zhang W; Zhang H; Zhong L; Zhou F; Guo G; He W
Cancer Immunol Immunother; 2023 Sep; 72(9):2991-3002. PubMed ID: 37289256
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience of PD-1 Inhibitors for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Retrospective Analysis of Patients in China.
Yu W; Geng M; Hao J; Yan Z; Mi JQ
Acta Haematol; 2023; 146(4):307-315. PubMed ID: 37023729
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
13. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Deng L; Li Z; Zhang H; Huang H; Hu J; Liu L; Liu T; Jin J; Zhu Z; Li W; Huang Z; Huang W; Zhou K; Yang H; Zhang M; Ding K; Zhou H; Hu Y; Shuang Y; Cao J; Gao S; Li D; Sun Z; Zhang Q; Yi S; Ji C; Zhang L; Hou C; Du Y; Wang W; Zhao R; Song Y; Zhu J
Am J Hematol; 2023 Nov; 98(11):1742-1750. PubMed ID: 37647123
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.
Huang H; Zhu J; Yao M; Kim TM; Yoon DH; Cho SG; Eom HS; Lim ST; Yeh SP; Song Y; Kwong YL; Kim JS; Jin J; Shi Y; Kim H; Qing M; Zhou T; Gao G; Dong Z; Qi M; Kim WS
J Hematol Oncol; 2021 Feb; 14(1):25. PubMed ID: 33588922
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study.
Wu J; Song Y; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
Int J Cancer; 2022 Mar; 150(6):984-992. PubMed ID: 34674396
[TBL] [Abstract][Full Text] [Related]
16. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Zhao X; Wang D; Zhang P; Wang Y; Wang L; Liu T; Zhang Y; Shen Z; Huang J; Zhu J
Clin Cancer Res; 2022 Mar; 28(6):1147-1156. PubMed ID: 34716199
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
Shi Y; Wu J; Wang Z; Zhang L; Wang Z; Zhang M; Cen H; Peng Z; Li Y; Fan L; Guo Y; Ma L; Cui J; Gao Y; Yang H; Zhang H; Wang L; Zhang W; Zhang H; Xie L; Jiang M; Zhou H; Shuang Y; Su H; Ke X; Jin C; Du X; Du X; Liu L; Xi Y; Ge Z; Feng R; Zhang Y; Zhou S; Xie F; Wang Q
J Hematol Oncol; 2021 Jan; 14(1):12. PubMed ID: 33436023
[TBL] [Abstract][Full Text] [Related]
18. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).
Tao R; Fan L; Song Y; Hu Y; Zhang W; Wang Y; Xu W; Li J
Signal Transduct Target Ther; 2021 Oct; 6(1):365. PubMed ID: 34702811
[TBL] [Abstract][Full Text] [Related]
19. Penpulimab: First Approval.
Dhillon S
Drugs; 2021 Dec; 81(18):2159-2166. PubMed ID: 34813051
[TBL] [Abstract][Full Text] [Related]
20. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.
Zheng Y; Mislang ARA; Coward J; Cosman R; Cooper A; Underhill C; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Jin X; Li B; Wang ZM; Kwek KY; Xia D; Xia Y; Xu N
Cancer Immunol Immunother; 2022 Oct; 71(10):2371-2379. PubMed ID: 35165764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
